gene

CDKN2A

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CDKN2A: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

468Connections

3Hypotheses

2Analyses

50Outgoing

50Incoming

0Experiments

2Debates

Summary

CDKN2A is a gene implicated in neurodegeneration research. Key relationships include: associated with, inhibits, activates. Associated with Aging, Als, Alzheimer. Connected to 223 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	CDKN2A
Chromosome	9p21.3
Function	is a 156-amino acid protein composed of ankyrin repeat domains that adopt a highly twisted, left-handed helix structure[@li2019].
Molecular Weight	16 kDa
Amino Acids	156 aa
Pathways	Glycolysis, Tgf-Β
UniProt ID	P42771
NCBI Gene ID	1029
Ensembl ID	ENSG00000147883
GeneCards	CDKN2A
Human Protein Atlas	CDKN2A
p12^INK4a^	Alternatively spliced variant with truncated N-terminus
Associated Diseases	Aging, Als, Alzheimer, Atherosclerosis, Cancer, Carcinoma
Known Drugs/Compounds	rapamycin
Interactions	AGING, AKT, AKT3, AND, APC, APOPTOSIS
SciDEX Hypotheses	Hippocampal-Cortical Transcriptomic Divergence Rev Senescence-Tau Decoupling Therapy
KG Connections	468 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: CDKN2A — AlphaFold P42771 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (2)

Knowledge base pages for this entity

Canonical Page

cdkn2a

gene · 1625 words

→

CDKN2A Protein

protein · 2330 words

→

Pathway Diagram

graph TD
    CDKN2A["CDKN2A"]
    CDKN2A -->|"inhibits"| cell_cycle_progression["cell cycle progression"]
    CDKN2A -->|"causes"| ESCC["ESCC"]
    CDKN2A -->|"target for"| Carcinoma["Carcinoma"]
    CDKN2A -->|"target for"| Cancer["Cancer"]
    CDKN2A -->|"target for"| Tumor["Tumor"]
    CDKN2A -->|"activates"| Als["Als"]
    CDKN2A -->|"expressed in"| Senescence["Senescence"]
    CDKN2A -->|"expressed in"| Lymphoma["Lymphoma"]
    FGFR1["FGFR1"] -->|"target for"| CDKN2A
    SOX2["SOX2"] -->|"target for"| CDKN2A
    CDK4["CDK4"] -->|"inhibits"| CDKN2A
    RB1["RB1"] -->|"inhibits"| CDKN2A
    BIN1["BIN1"] -->|"expressed in"| CDKN2A
    IGF1["IGF1"] -->|"regulates"| CDKN2A

Outgoing (364)

Target	Relation	Type	Str
benchmark_ot_ad_answer_key:CDKN2A	data_in	dataset_row	0.00
ds-83b31ef18d49	provides_data_for	dataset	1.00
Als	associated_with	disease	0.95
ESCC	causes	disease	0.90
cell cycle progression	inhibits	pathway	0.90
Autophagosome	associated_with	cell_type	0.90
Cellular Senescence	associated_with	phenotype	0.90
CD3+ T cells	expressed_in	cell_type	0.90
Tumor	risk_factor_for	disease	0.85
High-Grade Serous Ovarian Cancer	biomarker_for	disease	0.85
Pulmonary Vascular Endothelial Cell Senescence	biomarker_for	process	0.85
Tumor	inhibits	disease	0.85
Cancer	activates	disease	0.85
Tumor	activates	disease	0.85
Senescence	mediates	process	0.85
Cancer	associated_with	disease	0.85
Cellular Senescence	biomarker_for	process	0.80
Senescence	biomarker_for	process	0.80
CANCER	associated_with	gene	0.80
CANCER	activates	gene	0.80
Cancer	treats	disease	0.75
Tumor	therapeutic_target	disease	0.75
Alzheimer	associated_with	disease	0.75
Tumor	associated_with	disease	0.75
Glioblastoma	associated_with	disease	0.75
Als	activates	disease	0.75
Als	therapeutic_target	disease	0.75
TP53	associated_with	gene	0.70
OVERVIEW	treats	gene	0.70
TP53	activates	gene	0.70
BRCA1	associated_with	gene	0.70
BAP1	associated_with	gene	0.70
GENES	activates	gene	0.70
POT1	associated_with	gene	0.70
hippocampal neurodegeneration	biomarker_for	phenotype	0.70
GBM	associated_with	gene	0.70
CDK4	associated_with	gene	0.70
EGFR	associated_with	gene	0.70
ROS	activates	gene	0.70
CANCER	treats	gene	0.70
DNA	activates	gene	0.70
P16	inhibits	gene	0.70
GENES	associated_with	gene	0.70
ALZHEIMER'S DISEASE	associated_with	gene	0.70
Aging	therapeutic_target	disease	0.65
Ms	associated_with	disease	0.65
Senescence	expressed_in	disease	0.65
Carcinoma	expressed_in	disease	0.65
Aging	associated_with	disease	0.65
Neurodegeneration	associated_with	disease	0.65

Incoming (104)

Source	Relation	Type	Str
benchmark_ot_ad_answer_key:CDKN2A	data_in	dataset_row	0.00
ds-83b31ef18d49	data_in	dataset	1.00
SQSTM1	mediates	protein	0.95
MIR31HG	regulates	gene	0.90
h-08a79bc5	targets_gene	hypothesis	0.90
Polygonatum Sibiricum Polysaccharide	downregulates	compound	0.85
Autophagy Deficiency	causes	phenotype	0.85
DAPK1	regulates	gene	0.80
telomere shortening	upregulates	phenotype	0.80
SQSTM1	binds_to	gene	0.80
PTEN	associated_with	gene	0.80
MIR31HG	correlates_with	gene	0.75
TERT	associated_with	gene	0.70
TP53	interacts_with	gene	0.60
SOX11	therapeutic_target	gene	0.60
MYC	therapeutic_target	gene	0.60
KMT2D	interacts_with	gene	0.60
NSD2	interacts_with	gene	0.60
NOTCH2	interacts_with	gene	0.60
NFKBIE	interacts_with	gene	0.60
OVERVIEW	associated_with	gene	0.60
SOX10	associated_with	gene	0.60
NF1	associated_with	gene	0.60
APC	activates	gene	0.60
TP53	activates	gene	0.60
PMS2	activates	gene	0.60
CACNA1G	biomarker_for	gene	0.60
ARID1A	activates	gene	0.60
SGCE	associated_with	gene	0.60
NLRP3	regulates	gene	0.60
SLC31A2	regulates	gene	0.60
RAB23	associated_with	gene	0.60
ATRX	associated_with	gene	0.60
ATG	activates	gene	0.60
PTEN	activates	gene	0.60
GBM	associated_with	gene	0.60
CDKN1A	associated_with	gene	0.60
CD19	therapeutic_target	gene	0.60
ROS	associated_with	gene	0.60
rapamycin	targets	drug	0.60
IGF1	regulates	gene	0.60
APOPTOSIS	associated_with	gene	0.60
NEURODEGENERATION	associated_with	gene	0.60
AND	interacts_with	gene	0.60
CYCLIN D1	therapeutic_target	gene	0.60
TAU	associated_with	gene	0.60
DNA	biomarker_for	gene	0.60
CANCER	activates	gene	0.60
AND	biomarker_for	gene	0.60
NOTCH1	therapeutic_target	gene	0.60

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Hippocampal-Cortical Transcriptomic Divergence Reveals Accel	0.680	Alzheimer disease	Allen Mouse Brain Aging Atlas: cross-age
Epigenetic Bivalency at CDKN2A Locus Distinguishes Senescent	0.630	neurodegeneration	How can senescent microglia be molecular
Senescence-Tau Decoupling Therapy	0.585	neurodegeneration	Gene expression changes in aging mouse b

Mentioning Analyses (2)

Scientific analyses that reference this entity

Allen Mouse Brain Aging Atlas: cross-age gene expression analysis

neurodegeneration | 2026-04-23 | 8 hypotheses Top: 0.680

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

neurodegeneration | 2026-04-03 | 45 hypotheses Top: 0.990

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (5)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Uncovering the signatures of aging and senescence in the human dorsolateral pref [PMID:41576945]	Sloan NX, Mares J, Daly AC, Grier S, Haq	Cell Genom	2026
The Diagnostic Trap in Radiation-Induced Mesothelioma: Kinetic-Morphological Dec [PMID:41595142]	Fujita N, Fujita K, Osumi H, Takefuji Y	Cancers	2026
The prognostic impact of CDKN2A/B hemizygous deletions in meningioma. [PMID:41671098]	Ippen FM, Hielscher T, Patel A, Friedel	Neuro Oncol	2026
Cdkn2a/p16Ink4a loss impairs Spatial memory independently of Alzheimer's-associa [PMID:41741874]	Stephan P, Plassard D, Keyes WM, Hérault	Cell Mol Life Sci	2026
Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and c [PMID:41895394]	Xia X, Yi F, Zhang R, Wu R, Zhang X et a	Exp Neurol	2026

Debates (2)

Multi-agent debates referencing this entity

How does gene expression change across age groups (young/middle/old) in hippocam

active · Rounds: 4 · Score: 1.00 · 2026-04-24

What gene expression changes in the aging mouse brain predict neurodegenerative

closed · Rounds: 4 · Score: 0.95 · 2026-04-03